5、消化系统肿瘤消化系统肿瘤 (26).pdf
《5、消化系统肿瘤消化系统肿瘤 (26).pdf》由会员分享,可在线阅读,更多相关《5、消化系统肿瘤消化系统肿瘤 (26).pdf(5页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。
1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYLenvatinib plus toripalimab as first-linetreatment for advanced intrahepaticRights&PermissionsOPTIONS&TOOLSExport Citati
2、onTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article Toolscholangiocarcinoma:A single-arm,phase 2trial.Zhou Jian,Jia Fan,Guo-Ming Shi,Xiao-Yong Huang,Dong Wu,Fei Liang,.Show MoreAbstract Disclosures4099Background:Lenvatinib monotherap
3、y andlenvatinib plus PD-1 antibody have shown someclinical benefit for advanced intrahepaticcholangiocarcinoma(ICC)in the second-linesetting.Our study assesses the role of lenvatinibplus toripalimab(PD-1 antibody)for advanced ICCpatients as the first line therapy.Methods:Patients(pts)with locally ad
4、vanced or metastaticICC received 12 mg/day(Body Weight 60 kg)or 8mg/day(Body Weight 60 kg)oral lenvatinib dailyplus 240 mg intravenous toripalimab every 3COMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.4099Journal of Clinical Oncology 39,no.15_suppl(May 20,202
5、1)4099-4099.Published online May 28,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified
6、 or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the B
7、each inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractData from ESMO,GU CancersSymposium Highlight Progress inKidney Cancer TreatmentTeresa Alonso Gordoa et al.,ASCODaily News,2021Phase Ib Study of Lenvatinib PlusPembrolizumab in Patients WithUnre
8、sectable HepatocellularCarcinomaRichard S.Finn et al.,J Clin Oncol,2020ESMO 2019:Ivosidenib in IDH1-Mutated AdvancedCholangiocarcinomaBy The ASCO Post Staff,The ASCOPost,2019weeks.The primary endpoint was objectiveresponse rate(ORR)and evaluated according toResponse Evaluation Criteria In Solid Tumo
9、rsversion 1.1(RECIST v1.1).Secondary endpointsincluded safety,progression-free survival(PFS)and overall survival(OS).Treatment continueduntil confirmed disease progression,unacceptabletoxicity,or voluntary withdrawal.This trial isregistered with ClinicalTrials.gov(NCT04361331).Results:From March 202
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 5、消化系统肿瘤消化系统肿瘤 26 消化系统 肿瘤 26
限制150内